Locally advanced prostate cancer: Three-dimensional magnetic resonance spectroscopy to monitor prostate response to therapy

Anna Lia Valentini, Benedetta Gui, Giuseppe Roberto D'Agostino, Giancarlo Mattiucci, Valeria Clementi, Ippolita Valentina Di Molfetta, Pierluigi Bonomo, Giovanna Mantini

Research output: Contribution to journalArticle

Abstract

Purpose: To correlate results of three-dimensional magnetic resonance spectroscopic imaging (MRSI) with prostate-specific antigen (PSA) levels and time since external beam irradiation (EBRT) in patients treated with long-term hormone therapy (HT) and EBRT for locally advanced disease to verify successful treatment by documenting the achievement of metabolic atrophy (MA). Methods and Materials: Between 2006 and 2008, 109 patients were consecutively enrolled. MA was assessed by choline and citrate peak area-to-noise-ratio 1.5:1 or choline signal-to-noise-ratio >5:1. To test the strength of association between MRSI results and the time elapsed since EBRT (TEFRT), PSA levels, Gleason score (GS), and stage, logistic regression (LR) was performed. p value 2 years. MA was detected in 54.1% of patients of group 1, 88.9% of group 2, and in 94.5% of group 3 (100% when PSA nadir was reached). CM was detected in 50% of patients with reached PSA nadir in group 1. Local relapse was found in 3 patients previously showing CM at long TEFRT. Conclusion: MA detection, indicative of successful treatment because growth of normal or abnormal cells cannot occur without metabolism, increases with decreasing PSA levels and increasing time on HT after EBRT. This supports long-term HT in advanced prostate cancer. Larger study series are needed to assess whether MRSI could predict local relapse by detecting CM at long TEFRT.

Original languageEnglish
Pages (from-to)719-724
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume84
Issue number3
DOIs
Publication statusPublished - Nov 1 2012

Fingerprint

magnetic resonance spectroscopy
atrophy
antigens
Prostate-Specific Antigen
Prostate
therapy
Prostatic Neoplasms
Magnetic Resonance Spectroscopy
cancer
Atrophy
hormones
magnetic resonance
choline
irradiation
Magnetic Resonance Imaging
Hormones
Choline
Therapeutics
Recurrence
Neoplasm Grading

Keywords

  • 3D magnetic resonance spectroscopy
  • External beam irradiation
  • Hormone therapy
  • Metabolic atrophy
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Locally advanced prostate cancer : Three-dimensional magnetic resonance spectroscopy to monitor prostate response to therapy. / Valentini, Anna Lia; Gui, Benedetta; D'Agostino, Giuseppe Roberto; Mattiucci, Giancarlo; Clementi, Valeria; Di Molfetta, Ippolita Valentina; Bonomo, Pierluigi; Mantini, Giovanna.

In: International Journal of Radiation Oncology Biology Physics, Vol. 84, No. 3, 01.11.2012, p. 719-724.

Research output: Contribution to journalArticle

Valentini, Anna Lia ; Gui, Benedetta ; D'Agostino, Giuseppe Roberto ; Mattiucci, Giancarlo ; Clementi, Valeria ; Di Molfetta, Ippolita Valentina ; Bonomo, Pierluigi ; Mantini, Giovanna. / Locally advanced prostate cancer : Three-dimensional magnetic resonance spectroscopy to monitor prostate response to therapy. In: International Journal of Radiation Oncology Biology Physics. 2012 ; Vol. 84, No. 3. pp. 719-724.
@article{4d4891418b9d48bea1c4b5b221fa1c09,
title = "Locally advanced prostate cancer: Three-dimensional magnetic resonance spectroscopy to monitor prostate response to therapy",
abstract = "Purpose: To correlate results of three-dimensional magnetic resonance spectroscopic imaging (MRSI) with prostate-specific antigen (PSA) levels and time since external beam irradiation (EBRT) in patients treated with long-term hormone therapy (HT) and EBRT for locally advanced disease to verify successful treatment by documenting the achievement of metabolic atrophy (MA). Methods and Materials: Between 2006 and 2008, 109 patients were consecutively enrolled. MA was assessed by choline and citrate peak area-to-noise-ratio 1.5:1 or choline signal-to-noise-ratio >5:1. To test the strength of association between MRSI results and the time elapsed since EBRT (TEFRT), PSA levels, Gleason score (GS), and stage, logistic regression (LR) was performed. p value 2 years. MA was detected in 54.1{\%} of patients of group 1, 88.9{\%} of group 2, and in 94.5{\%} of group 3 (100{\%} when PSA nadir was reached). CM was detected in 50{\%} of patients with reached PSA nadir in group 1. Local relapse was found in 3 patients previously showing CM at long TEFRT. Conclusion: MA detection, indicative of successful treatment because growth of normal or abnormal cells cannot occur without metabolism, increases with decreasing PSA levels and increasing time on HT after EBRT. This supports long-term HT in advanced prostate cancer. Larger study series are needed to assess whether MRSI could predict local relapse by detecting CM at long TEFRT.",
keywords = "3D magnetic resonance spectroscopy, External beam irradiation, Hormone therapy, Metabolic atrophy, Prostate cancer",
author = "Valentini, {Anna Lia} and Benedetta Gui and D'Agostino, {Giuseppe Roberto} and Giancarlo Mattiucci and Valeria Clementi and {Di Molfetta}, {Ippolita Valentina} and Pierluigi Bonomo and Giovanna Mantini",
year = "2012",
month = "11",
day = "1",
doi = "10.1016/j.ijrobp.2011.12.089",
language = "English",
volume = "84",
pages = "719--724",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Locally advanced prostate cancer

T2 - Three-dimensional magnetic resonance spectroscopy to monitor prostate response to therapy

AU - Valentini, Anna Lia

AU - Gui, Benedetta

AU - D'Agostino, Giuseppe Roberto

AU - Mattiucci, Giancarlo

AU - Clementi, Valeria

AU - Di Molfetta, Ippolita Valentina

AU - Bonomo, Pierluigi

AU - Mantini, Giovanna

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Purpose: To correlate results of three-dimensional magnetic resonance spectroscopic imaging (MRSI) with prostate-specific antigen (PSA) levels and time since external beam irradiation (EBRT) in patients treated with long-term hormone therapy (HT) and EBRT for locally advanced disease to verify successful treatment by documenting the achievement of metabolic atrophy (MA). Methods and Materials: Between 2006 and 2008, 109 patients were consecutively enrolled. MA was assessed by choline and citrate peak area-to-noise-ratio 1.5:1 or choline signal-to-noise-ratio >5:1. To test the strength of association between MRSI results and the time elapsed since EBRT (TEFRT), PSA levels, Gleason score (GS), and stage, logistic regression (LR) was performed. p value 2 years. MA was detected in 54.1% of patients of group 1, 88.9% of group 2, and in 94.5% of group 3 (100% when PSA nadir was reached). CM was detected in 50% of patients with reached PSA nadir in group 1. Local relapse was found in 3 patients previously showing CM at long TEFRT. Conclusion: MA detection, indicative of successful treatment because growth of normal or abnormal cells cannot occur without metabolism, increases with decreasing PSA levels and increasing time on HT after EBRT. This supports long-term HT in advanced prostate cancer. Larger study series are needed to assess whether MRSI could predict local relapse by detecting CM at long TEFRT.

AB - Purpose: To correlate results of three-dimensional magnetic resonance spectroscopic imaging (MRSI) with prostate-specific antigen (PSA) levels and time since external beam irradiation (EBRT) in patients treated with long-term hormone therapy (HT) and EBRT for locally advanced disease to verify successful treatment by documenting the achievement of metabolic atrophy (MA). Methods and Materials: Between 2006 and 2008, 109 patients were consecutively enrolled. MA was assessed by choline and citrate peak area-to-noise-ratio 1.5:1 or choline signal-to-noise-ratio >5:1. To test the strength of association between MRSI results and the time elapsed since EBRT (TEFRT), PSA levels, Gleason score (GS), and stage, logistic regression (LR) was performed. p value 2 years. MA was detected in 54.1% of patients of group 1, 88.9% of group 2, and in 94.5% of group 3 (100% when PSA nadir was reached). CM was detected in 50% of patients with reached PSA nadir in group 1. Local relapse was found in 3 patients previously showing CM at long TEFRT. Conclusion: MA detection, indicative of successful treatment because growth of normal or abnormal cells cannot occur without metabolism, increases with decreasing PSA levels and increasing time on HT after EBRT. This supports long-term HT in advanced prostate cancer. Larger study series are needed to assess whether MRSI could predict local relapse by detecting CM at long TEFRT.

KW - 3D magnetic resonance spectroscopy

KW - External beam irradiation

KW - Hormone therapy

KW - Metabolic atrophy

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84866740397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866740397&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2011.12.089

DO - 10.1016/j.ijrobp.2011.12.089

M3 - Article

C2 - 22436789

AN - SCOPUS:84866740397

VL - 84

SP - 719

EP - 724

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -